- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Do | Aktionäre von Impact Biomedical bestätigen Direktoren und Wirtschaftsprüfer auf Jahreshauptversammlung | 1 | Investing.com Deutsch | ||
| 18.08. | Impact Biomedical announces 3F US patent issue | 1 | Seeking Alpha | ||
| 18.08. | Impact Biomedical Inc (IBO) Announces 3F US Patent Issue | 194 | GlobeNewswire (Europe) | HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition... ► Artikel lesen | |
| 14.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.06. | DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger | 225 | GlobeNewswire (Europe) | NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management... ► Artikel lesen | |
| 23.06. | Impact Biomedical-Aktie steigt nach Fusionsvereinbarung mit Dr Ashleys | 11 | Investing.com Deutsch | ||
| 23.06. | Impact Biomedical stock soars after merger deal with Dr Ashleys | 1 | Investing.com | ||
| 23.06. | IMPACT BIOMEDICAL INC; Dr Ashleys Limited: Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger | 347 | GlobeNewswire (Europe) | A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical... ► Artikel lesen | |
| 23.06. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.03. | Impact Biomedical Inc. Announcement Stock Activity/Pricing | 290 | GlobeNewswire (Europe) | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 769 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 379 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 23,150 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 18,205 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,78 | 0,00 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| NUVALENT | 95,87 | +4,21 % | Nuvalent to present zidesamtinib patient data at lung cancer conference | ||
| ADMA BIOLOGICS | 14,030 | 0,00 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| AMYLYX PHARMACEUTICALS | 12,460 | 0,00 % | Amylyx targets avexitide launch in 2027 with recruitment completion for LUCIDITY now expected in Q1 2026 | ||
| EVOTEC | 5,590 | 0,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,605 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,140 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,920 | 0,00 % | Taysha Gene Therapies: Citizens hebt Kursziel auf 8 US-Dollar an | ||
| MONTE ROSA THERAPEUTICS | 13,010 | 0,00 % | Monte Rosa Therapeutics reports Q3 results | ||
| QIAGEN | 37,340 | -0,04 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 172,03 | 0,00 % | Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline | ||
| KINIKSA PHARMACEUTICALS | 38,630 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 25,200 | 0,00 % | Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology... ► Artikel lesen |
IMPACT BIOMEDICAL INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,525 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.